May 09, 2023 / 08:40PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Welcome to the afternoon of the first day of the BofA Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst. And we're excited here to have Regeneron. Bob Landry, CFO is with us, and Ryan's on Stage, too. So Forward-looking statement, and then we'll get into prepared remarks and then Q&A. Does that work?
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
It does. Thanks, Geoff. We're excited to be here. Before we get started, I just want to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements.
A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events
Regeneron Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot